Haystack Oncology GmbH

Haystack Oncology is based on over 20 years of liquid biopsy technology and clinical development led by the scientists specialized in cancer genomics who first envisioned non-invasive cancer screening, MRD detection, and advanced disease therapy monitoring. Their discoveries have positively affected millions of lives, and companies that employ their technology have generated billions of dollars in enterprise value.